Cargando…
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. MATERIALS AND METHODS: From...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790860/ https://www.ncbi.nlm.nih.gov/pubmed/30999721 http://dx.doi.org/10.4143/crt.2018.671 |
_version_ | 1783458856313028608 |
---|---|
author | Lee, Jii Bum Park, Hyung Soon Park, Sejung Lee, Hyo Jin Kwon, Kyung A Choi, Young Jin Kim, Yu Jung Nam, Chung Mo Cho, Nam Hoon Kang, Beodeul Chung, Hyun Cheol Rha, Sun Young |
author_facet | Lee, Jii Bum Park, Hyung Soon Park, Sejung Lee, Hyo Jin Kwon, Kyung A Choi, Young Jin Kim, Yu Jung Nam, Chung Mo Cho, Nam Hoon Kang, Beodeul Chung, Hyun Cheol Rha, Sun Young |
author_sort | Lee, Jii Bum |
collection | PubMed |
description | PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. MATERIALS AND METHODS: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. RESULTS: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]). CONCLUSION: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events. |
format | Online Article Text |
id | pubmed-6790860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-67908602019-10-21 Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma Lee, Jii Bum Park, Hyung Soon Park, Sejung Lee, Hyo Jin Kwon, Kyung A Choi, Young Jin Kim, Yu Jung Nam, Chung Mo Cho, Nam Hoon Kang, Beodeul Chung, Hyun Cheol Rha, Sun Young Cancer Res Treat Original Article PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. MATERIALS AND METHODS: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. RESULTS: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]). CONCLUSION: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events. Korean Cancer Association 2019-10 2019-04-16 /pmc/articles/PMC6790860/ /pubmed/30999721 http://dx.doi.org/10.4143/crt.2018.671 Text en Copyright © 2019 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Jii Bum Park, Hyung Soon Park, Sejung Lee, Hyo Jin Kwon, Kyung A Choi, Young Jin Kim, Yu Jung Nam, Chung Mo Cho, Nam Hoon Kang, Beodeul Chung, Hyun Cheol Rha, Sun Young Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
title | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
title_full | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
title_fullStr | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
title_full_unstemmed | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
title_short | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
title_sort | temsirolimus in asian metastatic/recurrent non-clear cell renal carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790860/ https://www.ncbi.nlm.nih.gov/pubmed/30999721 http://dx.doi.org/10.4143/crt.2018.671 |
work_keys_str_mv | AT leejiibum temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT parkhyungsoon temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT parksejung temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT leehyojin temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT kwonkyunga temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT choiyoungjin temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT kimyujung temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT namchungmo temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT chonamhoon temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT kangbeodeul temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT chunghyuncheol temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma AT rhasunyoung temsirolimusinasianmetastaticrecurrentnonclearcellrenalcarcinoma |